-
-
Overview
-
Specificity: Detects human CD137. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Utomilumab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Bulk Human IgG2 Isotype Control (IB2) [ICH2255]
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
RUO Utomilumab is a fully-human IgG2 agonist mAb that selectively binds human 4-1BB/CD137, resulting in NF-κB activation and downstream cytokine production in cell lines and primary lymphocytes. Utomilumab can induce human leukocyte proliferation and has demonstrated significant antitumor activity as a single agent in human peripheral blood lymphocyte (PBL) SCID xenograft tumor models.
-
- Properties
- Applications
-
Overview